A ,New heart failure drug from Novartis cut the risk of both cardiovascular death and hospitalization by a fifth in keenly awaited study, boosting hopes for a product that is seen as a multi-million-dollar seller .
There have been little progress for more than a decade in treating chronic heart failure, in which the heart fails to pump blood around the body.
The study compared LCZ696 to an older drug already known to improve survival.
The European Society of Cardiology (ESC)
(adsbygoogle = window.adsbygoogle || []).push({});
Patients who took LCZ696 were 20 % less likely than those
on enalapril to die of cardiovascular causes and were also 21percent less likely to be admitted to hospital,according to the results presented at the conference of the European Society of Cardiology.
The new drug developed by Switzerland based 'Novartis' .
Comments
Post a Comment